Novo Nordisk, maker of Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time, citing slower growth in diabetes and obesity treatments ...

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Novo Nordisk lowered its forecasts due to slowing sales of its obesity drugs amid competition from Eli Lilly and generic ...

Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its ...

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

As Novo Nordisk fights a bidding war against Pfizer to acquire the obesity biotech Metsera, its new CEO dismissed claims that its offer would run into regulatory issues and said that Metsera would ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agreed-on deal ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...